Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Armin Schultz

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Clinical Drug Investigation|May 31, 2018
Multiple Rising Doses of Oral BI 425809, a GlyT1 Inhibitor, in Young and Elderly Healthy Volunteers: A Randomised, Double-Blind, Phase I Study Investigating Safety and PharmacokineticsViktoria Moschetti, Christina Schlecker, Sven Wind, et al.
Expert Opinion on Investigational Drugs|June 2, 2025
Phase 1 trials of BI 764198, a transient receptor potential channel 6 inhibitor, in healthy volunteers and participants with kidney impairmentArmin Schultz, Atef Halabi, Friedeborg Seitz, et al.
British Journal of Clinical Pharmacology|May 22, 2020
Midazolam microdosing applied in early clinical development for drug-drug interaction assessmentSabrina T Wiebe, Andreas Huennemeyer, Werner Kadus, et al.
British Journal of Clinical Pharmacology|September 28, 2020
Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton's tyrosine kinase, in Phase I clinical trials in healthy volunteersTobias Litzenburger, Jürgen Steffgen, Ewald Benediktus, et al.
Journal of Clinical Pharmacology|September 3, 2004
The effects of modifying in vivo cytochrome P450 3A (CYP3A) activity on etoricoxib pharmacokinetics and of etoricoxib administration on CYP3A activityNancy G B Agrawal, Catherine Z Matthews, Ralph S Mazenko, et al.
Nature|January 20, 2021
Publisher Correction: COVID-19 vaccine BNT162b1 elicits human antibody and T<sub>H</sub>1 T cell responsesUgur Sahin, Alexander Muik, Evelyna Derhovanessian, et al.
Nature|September 30, 2020
COVID-19 vaccine BNT162b1 elicits human antibody and T<sub>H</sub>1 T cell responsesUgur Sahin, Alexander Muik, Evelyna Derhovanessian, et al.
Nature|May 27, 2021
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humansUgur Sahin, Alexander Muik, Isabel Vogler, et al.
Nature|July 16, 2025
Author Correction: BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humansUğur Şahin, Alexander Muik, Isabel Vogler, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Clinical Drug Investigation|May 31, 2018
Multiple Rising Doses of Oral BI 425809, a GlyT1 Inhibitor, in Young and Elderly Healthy Volunteers: A Randomised, Double-Blind, Phase I Study Investigating Safety and PharmacokineticsViktoria Moschetti, Christina Schlecker, Sven Wind, et al.
Expert Opinion on Investigational Drugs|June 2, 2025
Phase 1 trials of BI 764198, a transient receptor potential channel 6 inhibitor, in healthy volunteers and participants with kidney impairmentArmin Schultz, Atef Halabi, Friedeborg Seitz, et al.
British Journal of Clinical Pharmacology|May 22, 2020
Midazolam microdosing applied in early clinical development for drug-drug interaction assessmentSabrina T Wiebe, Andreas Huennemeyer, Werner Kadus, et al.
British Journal of Clinical Pharmacology|September 28, 2020
Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton's tyrosine kinase, in Phase I clinical trials in healthy volunteersTobias Litzenburger, Jürgen Steffgen, Ewald Benediktus, et al.
Journal of Clinical Pharmacology|September 3, 2004
The effects of modifying in vivo cytochrome P450 3A (CYP3A) activity on etoricoxib pharmacokinetics and of etoricoxib administration on CYP3A activityNancy G B Agrawal, Catherine Z Matthews, Ralph S Mazenko, et al.
Nature|January 20, 2021
Publisher Correction: COVID-19 vaccine BNT162b1 elicits human antibody and T<sub>H</sub>1 T cell responsesUgur Sahin, Alexander Muik, Evelyna Derhovanessian, et al.
Nature|September 30, 2020
COVID-19 vaccine BNT162b1 elicits human antibody and T<sub>H</sub>1 T cell responsesUgur Sahin, Alexander Muik, Evelyna Derhovanessian, et al.
Nature|May 27, 2021
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humansUgur Sahin, Alexander Muik, Isabel Vogler, et al.
Nature|July 16, 2025
Author Correction: BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humansUğur Şahin, Alexander Muik, Isabel Vogler, et al.
Pageof 3